EVMN
EVMN
NYSE · Biotechnology

Evommune Inc

$21.36
+0.71 (+3.44%)
As of Jun 21, 10:19 PM ET ·
Financial Highlights (FY 2026)
Revenue
16.77M
Net Income
-88,834,401
Gross Margin
Profit Margin
-529.8%
Rev Growth
D/E Ratio
0.00
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 42.8% 42.8% 42.8%
Operating Margin -623.6% -23.9% -25.5% -21.7%
Profit Margin -529.8% -21.4% -26.9% -27.7%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 16.77M 78.02M 75.69M 85.24M
Gross Profit 33.42M 32.42M 36.51M
Operating Income -104,570,067 -18,680,583 -19,332,133 -18,489,345
Net Income -88,834,401 -16,723,517 -20,379,208 -23,619,828
Gross Margin 42.8% 42.8% 42.8%
Operating Margin -623.6% -23.9% -25.5% -21.7%
Profit Margin -529.8% -21.4% -26.9% -27.7%
Rev Growth -7.7% +21.3% +18.7%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 997.6K 82.29M 83.85M 90.36M
Total Equity 383.68M 243.06M 274.02M 233.46M
D/E Ratio 0.00 0.34 0.31 0.39
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -102,782,066 -28,105,243 -27,281,553 -29,215,509
Free Cash Flow -11,355,754 -12,035,038 -9,988,803